Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Alex A. Adjei, MD, PhD
Advertisement
Articles by Alex A. Adjei, MD, PhD
Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Advertisement
Latest Updated Articles
Dr. Adjei on the Need for Targeted Therapy EducationPublished: June 12th 2012 | Updated:
Dr. Adjei on Adverse Events From MEK InhibitorsPublished: September 11th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5